Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PEPCID AC | Johnson & Johnson | N-020325 OTC | 1995-04-28 | 2 products, RLD |
PEPCID AC | Johnson & Johnson | N-020801 OTC | 2007-12-17 | 1 products, RLD, RS |
PEPCID AC | Johnson & Johnson | N-020902 OTC | 1999-08-05 | 1 products |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PEPCID COMPLETE | Johnson & Johnson | N-020958 OTC | 2000-10-16 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DUEXIS | Horizon Therapeutics Public | N-022519 DISCN | 2011-04-23 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
acid controller | ANDA | 2024-12-30 |
acid reducer | ANDA | 2024-10-22 |
acid reducer complete | ANDA | 2022-07-19 |
acid reducer plus antacid | ANDA | 2024-12-20 |
acid relief | ANDA | 2023-10-02 |
amazon basic care acid reducer | ANDA | 2024-05-21 |
basic care acid reducer | ANDA | 2022-04-11 |
basic care dual action complete | ANDA | 2022-07-11 |
basic care famotidine | ANDA | 2020-02-19 |
basic care heartburn prevention | ANDA | 2022-01-05 |
Code | Description |
---|---|
S0028 | Injection, famotidine, 20 mg |
Drug common name | Famotidine |
INN | famotidine |
Description | Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.
|
Classification | Small molecule |
Drug class | H2-receptor antagonists (cimetidine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1 |
PDB | — |
CAS-ID | 76824-35-6 |
RxCUI | — |
ChEMBL ID | CHEMBL902 |
ChEBI ID | 4975 |
PubChem CID | 5702160 |
DrugBank | DB00927 |
UNII ID | 5QZO15J2Z8 (ChemIDplus, GSRS) |